Flonaspray

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flonaspray

Flonaspray is a pharmaceutical product defined by its specific active ingredient, Fluticasone Propionate, and its specialized nasal delivery system. As a single-ingredient product, its function is dedicated to delivering potent, localized anti-inflammatory action to the nasal passages. This medication is primarily identified as a specialized topical agent used to mitigate symptoms stemming from chronic nasal inflammation.


Quick Facts: Fluticasone Propionate

Property Description
Active ingredient Fluticasone Propionate
Form Metered Dose Nasal Spray (Aqueous Suspension)
Pharmacological class Nasal Corticosteroid / Glucocorticoid Steroid Medication
General purpose Reduces nasal swelling and irritation
Origin Synthetic trifluorinated corticosteroid

What Type of Medicine is Flonaspray (Fluticasone Propionate)?

Flonaspray is classified as a Glucocorticoid Steroid Medication, belonging specifically to the therapeutic category of Nasal Corticosteroids. This class of medicine is designed to reduce chronic nasal tissue inflammation.

Its active component, Fluticasone Propionate, is a synthetic trifluorinated corticosteroid chemically engineered to be a highly selective agonist at the glucocorticoid receptor. This substance is structurally designed for high topical anti-inflammatory potency combined with very low systemic absorption, minimizing the amount of drug that enters the general bloodstream from the site of intranasal application. This means the medicine works strongly where it is applied, minimizing effects elsewhere in the body.


Composition and Physical Form of Flonaspray

The medication is presented as a Metered Dose Nasal Spray containing microfine Fluticasone Propionate suspended in an aqueous base. This dosage form is designed to ensure precise and consistent administration of the medication. The active ingredient is dispersed as a microcrystalline suspension within a water-based solution, and the atomizing spray pump facilitates the even dispersion of the spray onto the nasal mucosa.


Fluticasone Propionate: Purpose and General Action

The primary purpose of Fluticasone Propionate is to achieve powerful localized anti-inflammatory effects and vasoconstrictor effects within the nasal passages. This action is accomplished by suppressing the underlying inflammatory processes that lead to swelling and irritation.

Its classification as an R01AD08 by the Anatomical Therapeutic Chemical (ATC) system places it in the category of nasal decongestants and other nasal preparations. The drug's primary function is related to clearing and improving nasal function. The resulting general benefit is the reduction of nasal congestion, swelling, and irritation, which helps clear the nasal passages and restores unimpeded breathing.

Regulatory References

  1. Fluticasone Nasal Spray: MedlinePlus Drug Information

What side effects are possible with Flonaspray?

Possible Side Effects and Safety Information

The safety profile for Flonaspray (fluticasone propionate nasal spray) is officially documented by government regulatory bodies, classifying adverse reactions by frequency and physiological system. Most reported events are localized to the area of administration.

Adverse Reaction Frequency

Adverse effects are classified according to regulatory standards:

  • Very Common (ge 1/10): The most frequent adverse reaction is epistaxis (nosebleeds).
  • Common (ge 1/100 to <1/10): Other frequently reported reactions include headache, nasal irritation or dryness, and throat irritation or dryness. Some patients may experience an unpleasant taste or smell.
  • Very Rare (<1/10,000): Serious, though highly infrequent, reactions include hypersensitivity reactions (e.g., angioedema, anaphylaxis, bronchospasm), nasal septal perforation, and effects related to systemic corticosteroid exposure, such as adrenal suppression or ocular conditions (glaucoma, cataracts).

Safety Considerations

The risk of systemic corticosteroid effects is explicitly tied to prolonged use at high doses. Patients using the medication long-term require monitoring for potential changes to the nasal mucosa or ocular health.

Specific safety considerations exist for certain groups. For pediatric patients, there is a documented potential for growth retardation, necessitating growth monitoring. For patients with severe hepatic impairment, caution is warranted due to the potential for increased systemic exposure. Use during pregnancy or lactation is based on a careful risk-benefit assessment due to inadequate evidence of human safety.

Overdose and Emergency Response

The official regulatory documents define the overdose profile for Fluticasone Propionate by distinguishing between acute emergency situations and the systemic effects of chronic high-dose exposure. The primary systemic risks documented relate to the endocrine system.

Documented Overdose Manifestations

The clinical findings of Hypercorticism and Adrenal Suppression may appear following the prolonged, chronic use of dosages that exceed the recommended level. These manifestations signify excessive systemic corticosteroid activity. No specific antidote is documented for Fluticasone Propionate overdose.

Management requires procedural steps: if Adrenal Suppression or Hypercorticism is confirmed, the label mandates the gradual discontinuation of the nasal spray. Continuous monitoring for signs of adrenal insufficiency is required following chronic high-dose exposure. Population-specific considerations include the monitoring of growth rate in pediatric patients and an increased risk of systemic effects in patients with severe liver disease.

When to Seek Immediate Help

Governmental guidance specifies that immediate medical attention must be sought in all cases of suspected overdose or accidental acute ingestion. Urgent action is mandated to Call 911 or local emergency services if the individual has collapsed or is not breathing. The Poison Control Center should be contacted immediately in all overdose cases. Additionally, immediate medical help is required if severe systemic hypersensitivity reactions, such as anaphylaxis or angioedema, are observed.

Therapeutic Uses of Flonaspray

Quick Facts

  • Targeted Conditions: Seasonal and perennial allergic rhinitis, non-allergic rhinitis, and nasal polyps.
  • Intended Action: Assists in the management of nasal discomfort and associated symptoms.
  • Primary Benefits: May provide relief from sneezing, nasal itching, runny nose, and nasal congestion.

What Flonaspray Treats: Main Uses and Benefits

Flonaspray (containing fluticasone propionate) is designated for the local management of certain nasal symptoms. This medication may be considered for use in patients experiencing symptoms related to seasonal or perennial allergic rhinitis, often referred to as hay fever or year-round allergies. Conditions that may be addressed include: sneezing, a runny nose, nasal congestion, and nasal itching.

Additionally, this drug is indicated for the management of the nasal symptoms of non-allergic rhinitis in adult and pediatric patients (aged 4 years and older).

In specific prescription formulations, it is further used in adults for the treatment of nasal polyps associated with chronic rhinosinusitis. The therapeutic goal of administration is to support a reduction in the severity of these symptoms, contributing to relief and improved comfort in the nasal passages.


Flonaspray is a formulation of fluticasone propionate. It is utilized to help manage the common manifestations of various nasal conditions.

It is important to remember that this medication supports symptom control but does not offer a definitive resolution for the underlying condition. Continued adherence to a clinician's direction is recommended to achieve and maintain therapeutic benefit.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Flonaspray?

This section details the population eligibility and restriction rules for Flonaspray (Fluticasone Propionate) as documented in official government regulatory labeling.

Absolute Contraindications

Flonaspray is contraindicated and must not be used by patients with a known hypersensitivity or allergy to fluticasone propionate or to any other inactive ingredient present in the nasal spray formulation.


Age-Based Eligibility

Age Group Regulatory Eligibility Status
Adults & Adolescents ( ge 12 years) Eligible for standard use.
Pediatric Patients (4 to 11 years) Eligible for standard use.
Children Under 4 Years Use is not recommended; safety and efficacy are not established.

Restricted or Conditional Use

Use of Flonaspray requires caution or restriction in certain populations as stated in official labeling:

  • Nasal Integrity: Must be avoided if the patient has recent nasal trauma, nasal ulcers, or has undergone recent nasal surgery, until healing is complete.
  • Infections: Use is restricted in the presence of an active localized nasal infection (e.g., Candida albicans), or active systemic infections such as tuberculosis or ocular herpes simplex.
  • Organ Function: Patients with severe hepatic impairment should use the medicine with caution, as the body may clear the drug more slowly.
  • Pregnancy & Lactation: Use during pregnancy or while breastfeeding is generally advised only if the benefit outweighs the potential risk, due to limited human safety data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Flonaspray (Fluticasone Propionate) is defined by its metabolic clearance pathway. The medication is primarily eliminated from the body by the Cytochrome P450 3A4 (CYP3A4) enzyme, establishing a crucial pharmacokinetic interaction domain. This dependence on CYP3A4 means co-administration with strong inhibitors of this enzyme can lead to a substantial increase in the systemic plasma concentration of Fluticasone Propionate. Such increased exposure carries the risk of systemic corticosteroid effects, including adrenal suppression.


Interaction-Related Restrictions

Classification Interacting Substance/Class Official Regulatory Statement
Major/Severe Risk Ritonavir (Potent CYP3A4 Inhibitor) Concomitant use is not recommended unless the potential benefit is judged to outweigh the documented risk.
Use With Caution Ketoconazole and other potent CYP3A4 inhibitors. Co-administration is expected to increase systemic exposure and requires careful consideration.
Food Restriction Grapefruit Juice Should be avoided as it can act as a strong CYP3A4 inhibitor, increasing systemic exposure risk.

The interaction profile emphasizes that the co-administration risk is particularly significant for the pediatric population, where reports of adrenal suppression have been specifically noted when combined with strong inhibitors. No mandatory dose separation or administration timing rules are documented; restrictions center on avoiding co-administration.

Mechanism of Action

Direct Modulation of Inflammatory Gene Expression

The mechanism begins inside the cell, where the active drug binds to and acts as an agonist at the intracellular Glucocorticoid Receptor (GR). This drug-receptor complex then moves into the nucleus, primarily engaging in trans-repression to inhibit the activity of key pro-inflammatory transcription factors, like NF-kappaB. This genomic action acts as a core molecular switch, modulating systems where pathway adjustment is required.

️ Suppression of the Inflammatory Cascade

By suppressing gene expression, the drug modifies early molecular steps that shape systemic physiological outcomes. This suppresses the synthesis and release of a broad spectrum of inflammatory mediators, including cytokines, leukotrienes, and histamine. This consequence reduces the survival and infiltration of inflammatory cells, such as eosinophils, at the site of application, resulting in decreased mucosal edema and vascular hyperpermeability.

⏳ Temporal Constraint of Action

This molecular mechanism is inherently reliant on the cellular processes of gene transcription and protein synthesis, which dictates a delayed onset for the full physiological effect. The mechanism influences feedback regulation within pathways, establishing a gradual but sustained modulation of pathway activity rather than initiating a rapid, minute-by-minute effect.

Dosage and Administration Information

The administration of Flonaspray (Fluticasone Propionate Nasal Spray) follows established protocols to ensure accurate dosage delivery. The medication is an aqueous suspension delivered via a metered-dose spray pump and is intended exclusively for the intranasal route.


Official Administration Guidelines

Parameter Instruction
Dosing Schedule Adults: The starting regimen is typically 2 sprays into each nostril once daily, providing 200 micrograms total. The dose is reduced to 1 spray per nostril once daily (100 micrograms) for maintenance once symptoms are controlled. Maximum daily doses are generally 200 micrograms, though 400 micrograms may be used for short periods in certain clinical circumstances.
Pediatric Rules For children aged 4 years and older, the starting dose is 1 spray into each nostril once daily (100 micrograms). Use is not established for children younger than 4 years.
Frequency & Duration The spray must be used at regular intervals to achieve its full effect, which may require 3 to 4 days of continuous daily use.

Procedural Requirements

Before each use, the device must be gently shaken.

The pump requires priming with several test sprays if it has not been used for 7 days or more. If a dose is missed, the standard procedure is to skip the missed dose and return to the regular schedule; double doses should not be administered. The spray unit must be discarded after the specified number of metered doses (e.g., 120 sprays), as consistent delivery is no longer guaranteed.

Recent Clinical Evidence

Research Evidence / Overview of studies for Flonaspray

This section describes the research base for Flonaspray (Fluticasone Propionate) by detailing the types of studies that have been conducted, the populations included, and the kinds of outcomes researchers monitored. The findings presented here describe group patterns and observed changes under specific study conditions; they are not individual predictions.


Evidence for use in Seasonal and Perennial Allergic Rhinitis

The research for allergic rhinitis, conditions characterized by fluctuating or episodic manifestations such as hay fever and year-round allergies, is supported by numerous standardized comparative studies. These studies have explored the medicine's use in both Adults, Adolescents, and Pediatric Patients (typically aged 4 years and older).

Researchers conducted numerous Randomized Controlled Trials (RCTs) and Systematic Reviews to explore how symptom measurements change over time. Studies examined outcomes related to physical discomfort, specifically changes in nasal symptom severity scores (TNSS), which measure congestion, sneezing, runny nose, and itching. Research also examined patient-reported outcomes for perceived discomfort, including metrics for ocular symptoms and overall Health-Related Quality of Life (QoL).

However, evidence quality varies across studies, and some reports describe that measured changes in certain pediatric subgroups did not demonstrate a change that met the defined threshold for a minimal clinically important difference. Long-term effects are not fully established beyond the one-year observation period described in some studies.


Evidence for use in Nasal Polyps

The research for nasal polyps, conditions marked by functional limitations associated with chronic rhinosinusitis, examined both physical and functional measures. This research was evaluated in Adult Patients with chronic rhinosinusitis and polyps, including those who were both new to treatment and post-operative.

Studies explored changes in objective polyp size or grade (polyp regression) and patient-reported outcomes describing perceived discomfort using functional measures like the Sinonasal Outcome Test (SNOT-22). Some evidence indicates that patterns observed may be less pronounced in individuals with more extensive forms of nasal polyposis. Anatomical factors suggest that distribution of the spray may be limited to certain deeper inflammatory sites.


Research Gaps and Areas of Uncertainty

The evidence highlights what is known — and what is still uncertain:

  • Long-term effects are not fully established, particularly the pattern of symptom control and recurrence after more than one year of continuous use.
  • Subgroup findings are uncertain regarding optimal delivery of the medicine to all sites of inflammation, especially in conditions like nasal polyps.
  • Research does not determine whether an individual will respond similarly to the group findings described in the trials, as study results are specific to the conditions under which they were conducted.

Key Studies & References

  1. FLUTICASONE PROPIONATE spray, metered - Official Drug Label Information (DailyMed/NIH)
  2. Topical corticosteroids for chronic rhinosinusitis with nasal polyposis: GRADE systematic review and network meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Flonaspray (FAQ)

Q: Can I use Flonaspray long-term, or is it only for short periods?

A: Official product information suggests that the nasal spray may be appropriate for long-term use. However, regulatory guidance suggests limiting continuous use to a specific period (e.g., six months for adults) or consulting a healthcare professional for long-term maintenance, due to the potential for systemic corticosteroid effects, such as eye changes.

Q: What should I do if the Flonaspray bottle seems clogged or won't spray correctly?

A: Official instructions provide guidance for maintenance, including re-priming the device if it has not been used for several days and providing instructions for cleaning the nozzle if it becomes clogged. Following these procedural steps helps maintain consistent dose delivery.

Q: Can Flonaspray cause headaches or feelings of dizziness?

A: According to the clinical trials described in regulatory documents, both headache and feelings of dizziness are listed as possible adverse reactions. These effects are listed in the adverse reaction profile. Any concerning or persistent side effects should be discussed with a healthcare provider.

Q: Does Flonaspray have any known effect on blood sugar levels?

A: The nasal spray is formulated for very low systemic absorption, meaning little of the drug enters the general bloodstream. However, the label contains a warning that very high doses or use by susceptible individuals could potentially lead to systemic corticosteroid effects, such as hypercorticism or adrenal suppression, which are systemic concerns associated with this class of medication.

Q: Do any studies suggest that Flonaspray loses effectiveness over time?

A: The maximum benefit of the spray is often reached only after several days of regular, continuous use. Official product information does not indicate a known risk of the medication suddenly losing its effectiveness, or tachyphylaxis, during continuous treatment.

Q: Does Flonaspray help with congestion that is not caused by allergies (non-allergic rhinitis)?

A: Official product labeling indicates that the active ingredient may be appropriate for more than just allergic conditions. The prescription labeling includes perennial non-allergic rhinitis—chronic congestion or inflammation not caused by allergens—as a documented indication for use in appropriate populations.

Q: Does Flonaspray interact with any common herbal remedies?

A: The regulatory labeling warns of a risk of increased systemic exposure when used with strong inhibitors of the CYP3A4 enzyme. This risk of increased systemic exposure may apply to certain herbal or dietary supplements known to affect the CYP3A4 enzyme system. It is important to review all current medications and supplements with a healthcare provider.

Q: Why do some people report stopping the use of Flonaspray?

A: Official product information contains a specific 'Stop Use' warning that lists certain conditions that may prompt a person to discontinue the spray. These conditions include developing a whistling sound in the nose, new vision problems, or experiencing severe or persistent nosebleeds.

Q: What happens if I accidentally use Flonaspray more than the recommended amount?

A: Official regulatory guidance advises contacting a Poison Control Center or seeking medical attention immediately if a user accidentally uses more than the recommended amount. This is a standard safety precaution for all medications.

Q: What is the main difference between Flonaspray and an oral antihistamine pill?

A: Flonaspray’s active ingredient is a glucocorticoid that is applied locally in the nose, where it works to target the underlying inflammatory process through multiple pathways. This is distinct from an oral antihistamine, which typically works systemically and primarily by blocking the effects of histamine.

Q: Can Flonaspray be used by people who also have asthma?

A: Official Over-the-Counter (OTC) labeling clarifies that the product is not intended for the treatment of asthma. A person with asthma should discuss the use of this medication with a healthcare professional before starting treatment.

Q: Is Flonaspray safe to use if I am driving or operating machinery?

A: Official product labeling does not contain a direct warning against driving or operating machinery. However, the adverse reaction profile lists side effects such as dizziness and headache, and users should be mindful of how the medication affects them.

Q: What is the shelf life of an opened bottle of Flonaspray?

A: The official instructions specify discarding the product after the labeled number of metered sprays has been administered. This is because dose consistency can no longer be guaranteed after that point. The spray should also be discarded if it has passed its expiration date.

Q: Are there any specific times of the day officially recommended for using Flonaspray?

A: The recommended dosing schedule is typically once daily or twice daily. If the schedule is twice daily, instructions usually emphasize spacing the doses evenly throughout the day, without mandating a specific time.

Q: What are the inactive components or ingredients of Flonaspray other than the main active substance?

A: The regulatory description explicitly lists the inactive ingredients in the aqueous suspension. These components typically include substances such as benzalkonium chloride (a preservative), dextrose, microcrystalline cellulose, and purified water.

Q: Can I use Flonaspray if I have a common cold, or is it strictly for allergies?

A: Patient information associated with the regulatory labeling clarifies that the nasal spray is not intended for the treatment of symptoms caused by the common cold. This medication is specifically indicated for allergy and chronic nasal inflammation management.

Q: What if Flonaspray accidentally gets into my eyes—is that harmful?

A: The patient instructions include a direct warning to avoid spraying the medication into the eyes or mouth. If accidental contact occurs, the eye should be rinsed.

Q: Is Flonaspray described as having a risk of dependency or rebound congestion?

A: Official regulatory information does not list addiction, dependency, or rhinitis medicamentosa (known as rebound congestion) as known risks of the product. Rebound congestion is a risk associated with certain other types of nasal sprays.

Q: Can I safely take Flonaspray if I am consuming alcohol?

A: Governmental health guidance in certain regions indicates that no direct interaction between the medication and alcohol is listed in the regulatory label. Therefore, consuming alcohol is generally considered acceptable while using fluticasone nasal spray.

Q: Do I need to clean the Flonaspray nozzle or applicator?

A: Official instructions for use include a specific section detailing how to clean the spray nozzle. This procedural step is recommended to maintain the pump's proper function and prevent clogs.

How should Flonaspray be stored and disposed of?

The storage and disposal of Flonaspray (Fluticasone Propionate Nasal Spray) must adhere strictly to regulatory labeling to maintain product stability and safety.

Storage Requirements

Temperature and Protection: Store the nasal spray at controlled room temperature, generally between 20 C and 25 C. The product must be protected from freezing, excessive heat, light, and moisture. Store the medication in its original container and ensure it is tightly closed.

Child Safety: For safety, keep Flonaspray out of the reach and sight of children.

Disposal and Stability

Discard Protocol: The product must be discarded after the expiration date or once the labeled number of sprays (typically 120) has been administered, even if liquid remains.

Disposal: Unused or expired medication must be disposed of by following instructions on the package or utilizing an authorized drug take-back program. The product should not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flonaspray found in:

A-Z Index: